trioxsalen may increase the photosensitizing activities of VERTEPORFIN.


5-Aminolevulinic acid may increase the photosensitizing activities of VERTEPORFIN.


TITANIUM DIOXIDE may increase the photosensitizing activities of VERTEPORFIN.


tiaprofenic acid may increase the photosensitizing activities of VERTEPORFIN.


Cyamemazine may increase the photosensitizing activities of VERTEPORFIN.


TEMOPORFIN may increase the photosensitizing activities of VERTEPORFIN.


methoxsalen may increase the photosensitizing activities of VERTEPORFIN.


Hexaminolevulinate may increase the photosensitizing activities of VERTEPORFIN.


BENZOPHENONE may increase the photosensitizing activities of VERTEPORFIN.


riboflavin may increase the photosensitizing activities of VERTEPORFIN.


carprofen may increase the photosensitizing activities of VERTEPORFIN.


Aclidinium may increase the anticholinergic activities of methscopolamine.


Aclidinium may increase the anticholinergic activities of hyoscyamine.


pirenzepine may increase the anticholinergic activities of mianserin.


TRIMETHAPHAN may increase the anticholinergic activities of mianserin.


sulpiride may increase the anticholinergic activities of ANISOTROPINE METHYLBROMIDE.


UMECLIDINIUM may increase the anticholinergic activities of Pentolinium.


mequitazine may increase the anticholinergic activities of procarbazine.


sulpiride may increase the anticholinergic activities of Methylscopolamine bromide.


Aclidinium may increase the anticholinergic activities of Atracurium besylate.


Tiotropium may increase the anticholinergic activities of biperiden.


Glycopyrronium may increase the anticholinergic activities of ipratropium.


sulpiride may increase the anticholinergic activities of pirenzepine.


Aclidinium may increase the anticholinergic activities of Tiotropium.


Pizotifen may increase the anticholinergic activities of AMPHETAMINE.


UMECLIDINIUM may increase the anticholinergic activities of Fesoterodine.


Tiotropium may increase the anticholinergic activities of Desloratadine.


sulpiride may increase the anticholinergic activities of oxyphenonium.


doxylamine may increase the anticholinergic activities of selegiline.


Glycopyrronium may increase the anticholinergic activities of pirenzepine.


ANISOTROPINE METHYLBROMIDE may increase the anticholinergic activities of mianserin.


UMECLIDINIUM may increase the anticholinergic activities of Vecuronium.


clemastine may increase the anticholinergic activities of isocarboxazid.


Glycopyrronium may increase the anticholinergic activities of Pentolinium.


doxylamine may increase the anticholinergic activities of procarbazine.


Aclidinium may increase the anticholinergic activities of procyclidine.


procyclidine may increase the anticholinergic activities of mianserin.


Tiotropium may increase the anticholinergic activities of tolterodine.


mecamylamine may increase the anticholinergic activities of mianserin.


Aclidinium may increase the anticholinergic activities of Pentolinium.


UMECLIDINIUM may increase the anticholinergic activities of ATROPINE.


UMECLIDINIUM may increase the anticholinergic activities of Butylscopolamine.


CYPROHEPTADINE may increase the anticholinergic activities of isocarboxazid.


propantheline may increase the anticholinergic activities of mianserin.


Glycopyrronium may increase the anticholinergic activities of Atracurium besylate.


Aclidinium may increase the anticholinergic activities of propantheline.


Glycopyrronium may increase the anticholinergic activities of TRIMETHAPHAN.


UMECLIDINIUM may increase the anticholinergic activities of pirenzepine.


doxylamine may increase the anticholinergic activities of isocarboxazid.


Glycopyrronium may increase the anticholinergic activities of scopolamine.


Glycopyrronium may increase the anticholinergic activities of ANISOTROPINE METHYLBROMIDE.


doxylamine may increase the anticholinergic activities of AMPHETAMINE.


mequitazine may increase the anticholinergic activities of Pirlindole.


sulpiride may increase the anticholinergic activities of UMECLIDINIUM.


mequitazine may increase the anticholinergic activities of Phenelzine.


Glycopyrronium may increase the anticholinergic activities of tubocurarine.


CYPROHEPTADINE may increase the anticholinergic activities of selegiline.


Aclidinium may increase the anticholinergic activities of ipratropium.


Pentolinium may increase the anticholinergic activities of mianserin.


UMECLIDINIUM may increase the anticholinergic activities of Aclidinium.


CYPROHEPTADINE may increase the anticholinergic activities of moclobemide.


sulpiride may increase the anticholinergic activities of tubocurarine.


UMECLIDINIUM may increase the anticholinergic activities of procyclidine.


doxylamine may increase the anticholinergic activities of rasagiline.


sulpiride may increase the anticholinergic activities of Trospium.


sulpiride may increase the anticholinergic activities of Atracurium besylate.


UMECLIDINIUM may increase the anticholinergic activities of ipratropium.


clemastine may increase the anticholinergic activities of furazolidone.


sulpiride may increase the anticholinergic activities of quinidine.


UMECLIDINIUM may increase the anticholinergic activities of GALLAMINE TRIETHIODIDE.


methscopolamine may increase the anticholinergic activities of mianserin.


Aclidinium may increase the anticholinergic activities of ANISOTROPINE METHYLBROMIDE.


Aclidinium may increase the anticholinergic activities of Propiverine.


Glycopyrronium may increase the anticholinergic activities of quinidine.


sulpiride may increase the anticholinergic activities of TRIMETHAPHAN.


Aclidinium may increase the anticholinergic activities of mianserin.


Tiotropium may increase the anticholinergic activities of Methylscopolamine bromide.


Tiotropium may increase the anticholinergic activities of mecamylamine.


clemastine may increase the anticholinergic activities of Pirlindole.


Glycopyrronium may increase the anticholinergic activities of Propiverine.


UMECLIDINIUM may increase the anticholinergic activities of methscopolamine.


Glycopyrronium may increase the anticholinergic activities of hyoscyamine.


oxyphenonium may increase the anticholinergic activities of mianserin.


Tiotropium may increase the anticholinergic activities of Fesoterodine.


sulpiride may increase the anticholinergic activities of propantheline.


Tiotropium may increase the anticholinergic activities of trihexyphenidyl.


hyoscyamine may increase the anticholinergic activities of mianserin.


doxylamine may increase the anticholinergic activities of Pirlindole.


Pizotifen may increase the anticholinergic activities of tranylcypromine.


Metixene may increase the anticholinergic activities of mianserin.


Glycopyrronium may increase the anticholinergic activities of ATROPINE.


Glycopyrronium may increase the anticholinergic activities of oxybutynin.


Glycopyrronium may increase the anticholinergic activities of oxyphenonium.


Tiotropium may increase the anticholinergic activities of Glycopyrronium.


Aclidinium may increase the anticholinergic activities of Trospium.


Pizotifen may increase the anticholinergic activities of furazolidone.


Aclidinium may increase the anticholinergic activities of tolterodine.


doxylamine may increase the anticholinergic activities of methylene blue.


UMECLIDINIUM may increase the anticholinergic activities of tolterodine.


Pizotifen may increase the anticholinergic activities of moclobemide.


UMECLIDINIUM may increase the anticholinergic activities of Trospium.


Aclidinium may increase the anticholinergic activities of Fesoterodine.


sulpiride may increase the anticholinergic activities of ipratropium.


UMECLIDINIUM may increase the anticholinergic activities of trihexyphenidyl.


Tiotropium may increase the anticholinergic activities of quinidine.


mequitazine may increase the anticholinergic activities of moclobemide.


Glycopyrronium may increase the anticholinergic activities of amantadine.


Propiverine may increase the anticholinergic activities of mianserin.


Tiotropium may increase the anticholinergic activities of procyclidine.


CYPROHEPTADINE may increase the anticholinergic activities of procarbazine.


sulpiride may increase the anticholinergic activities of Desloratadine.


Aclidinium may increase the anticholinergic activities of PIPECURONIUM.


Aclidinium may increase the anticholinergic activities of Vecuronium.


UMECLIDINIUM may increase the anticholinergic activities of mecamylamine.


trihexyphenidyl may increase the anticholinergic activities of mianserin.


Tiotropium may increase the anticholinergic activities of ethopropazine.


Glycopyrronium may increase the anticholinergic activities of PIPECURONIUM.


Tiotropium may increase the anticholinergic activities of propantheline.


Vecuronium may increase the anticholinergic activities of mianserin.


Tiotropium may increase the anticholinergic activities of ATROPINE.


UMECLIDINIUM may increase the anticholinergic activities of tropicamide.


Tiotropium may increase the anticholinergic activities of Pentolinium.


doxylamine may increase the anticholinergic activities of Toloxatone.


CYPROHEPTADINE may increase the anticholinergic activities of tranylcypromine.


UMECLIDINIUM may increase the anticholinergic activities of quinidine.


clemastine may increase the anticholinergic activities of moclobemide.


Tiotropium may increase the anticholinergic activities of Trospium.


Tiotropium may increase the anticholinergic activities of mianserin.


Aclidinium may increase the anticholinergic activities of Butylscopolamine.


sulpiride may increase the anticholinergic activities of hyoscyamine.


Tiotropium may increase the anticholinergic activities of methscopolamine.


Aclidinium may increase the anticholinergic activities of Glycopyrronium.


PIPECURONIUM may increase the anticholinergic activities of mianserin.


Aclidinium may increase the anticholinergic activities of oxyphenonium.


Pizotifen may increase the anticholinergic activities of procarbazine.


sulpiride may increase the anticholinergic activities of PIPECURONIUM.


Tiotropium may increase the anticholinergic activities of ipratropium.


sulpiride may increase the anticholinergic activities of Vecuronium.


Aclidinium may increase the anticholinergic activities of scopolamine.


CYPROHEPTADINE may increase the anticholinergic activities of AMPHETAMINE.


Glycopyrronium may increase the anticholinergic activities of Trospium.


Glycopyrronium may increase the anticholinergic activities of orphenadrine.


doxylamine may increase the anticholinergic activities of tranylcypromine.


orphenadrine may increase the anticholinergic activities of mianserin.


doxylamine may increase the anticholinergic activities of furazolidone.


Tiotropium may increase the anticholinergic activities of pirenzepine.


UMECLIDINIUM may increase the anticholinergic activities of oxyphenonium.


Glycopyrronium may increase the anticholinergic activities of Desloratadine.


ipratropium may increase the anticholinergic activities of mianserin.


CYPROHEPTADINE may increase the anticholinergic activities of rasagiline.


Glycopyrronium may increase the anticholinergic activities of mianserin.


sulpiride may increase the anticholinergic activities of tolterodine.


sulpiride may increase the anticholinergic activities of pancuronium.


UMECLIDINIUM may increase the anticholinergic activities of hyoscyamine.


UMECLIDINIUM may increase the anticholinergic activities of propantheline.


sulpiride may increase the anticholinergic activities of ethopropazine.


doxylamine may increase the anticholinergic activities of moclobemide.


Glycopyrronium may increase the anticholinergic activities of Methylscopolamine bromide.


Tiotropium may increase the anticholinergic activities of oxyphenonium.


pancuronium may increase the anticholinergic activities of mianserin.


UMECLIDINIUM may increase the anticholinergic activities of tubocurarine.


Aclidinium may increase the anticholinergic activities of Metixene.


clemastine may increase the anticholinergic activities of procarbazine.


Aclidinium may increase the anticholinergic activities of tubocurarine.


Glycopyrronium may increase the anticholinergic activities of trihexyphenidyl.


UMECLIDINIUM may increase the anticholinergic activities of Tiotropium.


Aclidinium may increase the anticholinergic activities of pirenzepine.


sulpiride may increase the anticholinergic activities of mecamylamine.


Aclidinium may increase the anticholinergic activities of Methylscopolamine bromide.


UMECLIDINIUM may increase the anticholinergic activities of cyclopentolate.


tropicamide may increase the anticholinergic activities of mianserin.


sulpiride may increase the anticholinergic activities of biperiden.


Aclidinium may increase the anticholinergic activities of TRIMETHAPHAN.


sulpiride may increase the anticholinergic activities of Propiverine.


UMECLIDINIUM may increase the anticholinergic activities of TRIMETHAPHAN.


UMECLIDINIUM may increase the anticholinergic activities of Atracurium besylate.


sulpiride may increase the anticholinergic activities of tropicamide.


Glycopyrronium may increase the anticholinergic activities of mecamylamine.


mequitazine may increase the anticholinergic activities of pargyline.


clemastine may increase the anticholinergic activities of rasagiline.


tolterodine may increase the anticholinergic activities of mianserin.


benztropine may increase the anticholinergic activities of mianserin.


UMECLIDINIUM may increase the anticholinergic activities of Metixene.


Tiotropium may increase the anticholinergic activities of orphenadrine.


UMECLIDINIUM may increase the anticholinergic activities of Propiverine.


Glycopyrronium may increase the anticholinergic activities of Fesoterodine.


Pizotifen may increase the anticholinergic activities of isocarboxazid.


Butylscopolamine may increase the anticholinergic activities of mianserin.


mequitazine may increase the anticholinergic activities of selegiline.


Aclidinium may increase the anticholinergic activities of quinidine.


Pizotifen may increase the anticholinergic activities of rasagiline.


CYPROHEPTADINE may increase the anticholinergic activities of Toloxatone.


GALLAMINE TRIETHIODIDE may increase the anticholinergic activities of mianserin.


Glycopyrronium may increase the anticholinergic activities of cyclopentolate.


CYPROHEPTADINE may increase the anticholinergic activities of methylene blue.


Glycopyrronium may increase the anticholinergic activities of procyclidine.


Aclidinium may increase the anticholinergic activities of trihexyphenidyl.


dicyclomine may increase the anticholinergic activities of mianserin.


Pizotifen may increase the anticholinergic activities of Pirlindole.


Aclidinium may increase the anticholinergic activities of mecamylamine.


Tiotropium may increase the anticholinergic activities of tubocurarine.


sulpiride may increase the anticholinergic activities of Tiotropium.


sulpiride may increase the anticholinergic activities of benztropine.


Aclidinium may increase the anticholinergic activities of tropicamide.


Pizotifen may increase the anticholinergic activities of selegiline.


Glycopyrronium may increase the anticholinergic activities of propantheline.


mequitazine may increase the anticholinergic activities of isocarboxazid.


UMECLIDINIUM may increase the anticholinergic activities of pancuronium.


sulpiride may increase the anticholinergic activities of Pentolinium.


UMECLIDINIUM may increase the anticholinergic activities of dicyclomine.


sulpiride may increase the anticholinergic activities of GALLAMINE TRIETHIODIDE.


UMECLIDINIUM may increase the anticholinergic activities of PIPECURONIUM.


UMECLIDINIUM may increase the anticholinergic activities of Desloratadine.


UMECLIDINIUM may increase the anticholinergic activities of mianserin.


doxylamine may increase the anticholinergic activities of pargyline.


clemastine may increase the anticholinergic activities of AMPHETAMINE.


mequitazine may increase the anticholinergic activities of rasagiline.


CYPROHEPTADINE may increase the anticholinergic activities of Pirlindole.


Atracurium besylate may increase the anticholinergic activities of mianserin.


ethopropazine may increase the anticholinergic activities of mianserin.


Pizotifen may increase the anticholinergic activities of Phenelzine.


mequitazine may increase the anticholinergic activities of Toloxatone.


Aclidinium may increase the anticholinergic activities of cyclopentolate.


mequitazine may increase the anticholinergic activities of AMPHETAMINE.


mequitazine may increase the anticholinergic activities of methylene blue.


Tiotropium may increase the anticholinergic activities of oxybutynin.


sulpiride may increase the anticholinergic activities of Metixene.


biperiden may increase the anticholinergic activities of mianserin.


sulpiride may increase the anticholinergic activities of dicyclomine.


Tiotropium may increase the anticholinergic activities of hyoscyamine.


scopolamine may increase the anticholinergic activities of mianserin.


Glycopyrronium may increase the anticholinergic activities of biperiden.


cyclopentolate may increase the anticholinergic activities of mianserin.


clemastine may increase the anticholinergic activities of pargyline.


Aclidinium may increase the anticholinergic activities of biperiden.


Glycopyrronium may increase the anticholinergic activities of ethopropazine.


Tiotropium may increase the anticholinergic activities of Butylscopolamine.


CYPROHEPTADINE may increase the anticholinergic activities of Phenelzine.


sulpiride may increase the anticholinergic activities of scopolamine.


Glycopyrronium may increase the anticholinergic activities of pancuronium.


sulpiride may increase the anticholinergic activities of ATROPINE.


Pizotifen may increase the anticholinergic activities of pargyline.


UMECLIDINIUM may increase the anticholinergic activities of biperiden.


sulpiride may increase the anticholinergic activities of methscopolamine.


mequitazine may increase the anticholinergic activities of tranylcypromine.


Aclidinium may increase the anticholinergic activities of dicyclomine.


CYPROHEPTADINE may increase the anticholinergic activities of pargyline.


doxylamine may increase the anticholinergic activities of Phenelzine.


UMECLIDINIUM may increase the anticholinergic activities of benztropine.


sulpiride may increase the anticholinergic activities of Glycopyrronium.


Trospium may increase the anticholinergic activities of mianserin.


tubocurarine may increase the anticholinergic activities of mianserin.


mequitazine may increase the anticholinergic activities of furazolidone.


clemastine may increase the anticholinergic activities of Phenelzine.


Aclidinium may increase the anticholinergic activities of GALLAMINE TRIETHIODIDE.


sulpiride may increase the anticholinergic activities of Butylscopolamine.


UMECLIDINIUM may increase the anticholinergic activities of orphenadrine.


clemastine may increase the anticholinergic activities of tranylcypromine.


ATROPINE may increase the anticholinergic activities of mianserin.


sulpiride may increase the anticholinergic activities of procyclidine.


Tiotropium may increase the anticholinergic activities of scopolamine.


sulpiride may increase the anticholinergic activities of trihexyphenidyl.


Aclidinium may increase the anticholinergic activities of benztropine.


Tiotropium may increase the anticholinergic activities of TRIMETHAPHAN.


Aclidinium may increase the anticholinergic activities of orphenadrine.


CYPROHEPTADINE may increase the anticholinergic activities of furazolidone.


quinidine may increase the anticholinergic activities of mianserin.


Glycopyrronium may increase the anticholinergic activities of tropicamide.


sulpiride may increase the anticholinergic activities of Aclidinium.


Glycopyrronium may increase the anticholinergic activities of dicyclomine.


Methylscopolamine bromide may increase the anticholinergic activities of mianserin.


Tiotropium may increase the anticholinergic activities of Metixene.


sulpiride may increase the anticholinergic activities of cyclopentolate.


oxybutynin may increase the anticholinergic activities of mianserin.


UMECLIDINIUM may increase the anticholinergic activities of ANISOTROPINE METHYLBROMIDE.


Aclidinium may increase the anticholinergic activities of Desloratadine.


Aclidinium may increase the anticholinergic activities of oxybutynin.


Tiotropium may increase the anticholinergic activities of benztropine.


UMECLIDINIUM may increase the anticholinergic activities of Glycopyrronium.


Glycopyrronium may increase the anticholinergic activities of Vecuronium.


UMECLIDINIUM may increase the anticholinergic activities of ethopropazine.


Glycopyrronium may increase the anticholinergic activities of methscopolamine.


Glycopyrronium may increase the anticholinergic activities of benztropine.


Glycopyrronium may increase the anticholinergic activities of tolterodine.


Tiotropium may increase the anticholinergic activities of dicyclomine.


Tiotropium may increase the anticholinergic activities of cyclopentolate.


Tiotropium may increase the anticholinergic activities of ANISOTROPINE METHYLBROMIDE.


Aclidinium may increase the anticholinergic activities of pancuronium.


Tiotropium may increase the anticholinergic activities of tropicamide.


Tiotropium may increase the anticholinergic activities of Propiverine.


UMECLIDINIUM may increase the anticholinergic activities of scopolamine.


clemastine may increase the anticholinergic activities of Toloxatone.


Tiotropium may increase the anticholinergic activities of GALLAMINE TRIETHIODIDE.


UMECLIDINIUM may increase the anticholinergic activities of oxybutynin.


clemastine may increase the anticholinergic activities of selegiline.


Tiotropium may increase the anticholinergic activities of Atracurium besylate.


sulpiride may increase the anticholinergic activities of Fesoterodine.


Glycopyrronium may increase the anticholinergic activities of GALLAMINE TRIETHIODIDE.


Glycopyrronium may increase the anticholinergic activities of Butylscopolamine.


Aclidinium may increase the anticholinergic activities of ethopropazine.


UMECLIDINIUM may increase the anticholinergic activities of Methylscopolamine bromide.


Desloratadine may increase the anticholinergic activities of mianserin.


Glycopyrronium may increase the anticholinergic activities of Metixene.


Tiotropium may increase the anticholinergic activities of PIPECURONIUM.


Tiotropium may increase the anticholinergic activities of Vecuronium.


Pizotifen may increase the anticholinergic activities of Toloxatone.


sulpiride may increase the anticholinergic activities of oxybutynin.


Tiotropium may increase the anticholinergic activities of pancuronium.


Pizotifen may increase the anticholinergic activities of methylene blue.


clemastine may increase the anticholinergic activities of methylene blue.


Aclidinium may increase the anticholinergic activities of ATROPINE.


The bioavailability of Estrone sulfate can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of prednisone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with Aluminium.


The bioavailability of PREDNICARBATE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with Aluminium hydroxide.


The bioavailability of prednisone can be decreased when combined with Almasilate.


The bioavailability of Fluprednidene can be decreased when combined with Magnesium trisilicate.


The bioavailability of hydrocortisone can be decreased when combined with Trometamol.


The bioavailability of fluocinonide can be decreased when combined with Magnesium trisilicate.


The bioavailability of DEFLAZACORT can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of methylprednisolone can be decreased when combined with Aluminium hydroxide.


The bioavailability of Mometasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with Magnesium trisilicate.


The bioavailability of Estrone sulfate can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of medrysone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of Tixocortol can be decreased when combined with Aluminium.


The bioavailability of betamethasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Halobetasol can be decreased when combined with Almasilate.


The bioavailability of flumethasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with Almasilate.


The bioavailability of fludrocortisone can be decreased when combined with Trometamol.


The bioavailability of formestane can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of alclometasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of desoximetasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of Fluticasone furoate can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of fluocinonide can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of Clobetasone can be decreased when combined with Trometamol.


The bioavailability of methylprednisolone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of hydrocortisone can be decreased when combined with Almasilate.


The bioavailability of diflorasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of amcinonide can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of equilin can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of medrysone can be decreased when combined with Aluminium hydroxide.


The bioavailability of Ciclesonide can be decreased when combined with Magnesium trisilicate.


The bioavailability of RIMEXOLONE can be decreased when combined with Almasilate.


The bioavailability of Tixocortol can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of RIMEXOLONE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with Magaldrate.


The bioavailability of Mometasone can be decreased when combined with Magaldrate.


The bioavailability of dexamethasone can be decreased when combined with Trometamol.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Halobetasol can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of prednisone can be decreased when combined with Trometamol.


The bioavailability of betamethasone can be decreased when combined with Almasilate.


The bioavailability of triamcinolone can be decreased when combined with Magaldrate.


The bioavailability of DESONIDE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of Clobetasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of diflorasone can be decreased when combined with Trometamol.


The bioavailability of halcinonide can be decreased when combined with Almasilate.


The bioavailability of difluprednate can be decreased when combined with Almasilate.


The bioavailability of DEFLAZACORT can be decreased when combined with Aluminium hydroxide.


The bioavailability of diflorasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of DEFLAZACORT can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of estrone can be decreased when combined with Aluminium hydroxide.


The bioavailability of flunisolide can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of PREDNICARBATE can be decreased when combined with Aluminium.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with Aluminium hydroxide.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of difluprednate can be decreased when combined with Trometamol.


The bioavailability of triamcinolone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of formestane can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of hydrocortisone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of flunisolide can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of paramethasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of CORTISONE ACETATE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of desoximetasone can be decreased when combined with Aluminium.


The bioavailability of formestane can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Fluticasone furoate can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Halobetasol can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of RIMEXOLONE can be decreased when combined with Aluminium.


The bioavailability of FLUOCORTOLONE can be decreased when combined with Magnesium trisilicate.


The bioavailability of difluprednate can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of prednisone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of betamethasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of medrysone can be decreased when combined with Trometamol.


The bioavailability of DEFLAZACORT can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of Estrone sulfate can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of amcinonide can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of desoximetasone can be decreased when combined with Magaldrate.


The bioavailability of dexamethasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of budesonide can be decreased when combined with Magnesium trisilicate.


The bioavailability of Fluticasone furoate can be decreased when combined with Magaldrate.


The bioavailability of formestane can be decreased when combined with Magaldrate.


The bioavailability of DESONIDE can be decreased when combined with Aluminium.


The bioavailability of RIMEXOLONE can be decreased when combined with Trometamol.


The bioavailability of methylprednisolone can be decreased when combined with Trometamol.


The bioavailability of flunisolide can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of PREDNICARBATE can be decreased when combined with Almasilate.


The bioavailability of fluocinonide can be decreased when combined with Magaldrate.


The bioavailability of Tixocortol can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of PREDNICARBATE can be decreased when combined with Magnesium trisilicate.


The bioavailability of flumethasone can be decreased when combined with Almasilate.


The bioavailability of diflorasone can be decreased when combined with Aluminium.


The bioavailability of fludrocortisone can be decreased when combined with Aluminium hydroxide.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of halcinonide can be decreased when combined with Magnesium trisilicate.


The bioavailability of Tixocortol can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of difluprednate can be decreased when combined with Magnesium trisilicate.


The bioavailability of prednisone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of diflorasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of FLUOCORTOLONE can be decreased when combined with Magaldrate.


The bioavailability of Clobetasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of flunisolide can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Tixocortol can be decreased when combined with Magnesium trisilicate.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of Halobetasol can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of CORTISONE ACETATE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of paramethasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of halcinonide can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of DESONIDE can be decreased when combined with Magnesium trisilicate.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of RIMEXOLONE can be decreased when combined with Magaldrate.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with Aluminium hydroxide.


The bioavailability of desoximetasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of Halobetasol can be decreased when combined with Aluminium hydroxide.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with Magnesium trisilicate.


The bioavailability of DEFLAZACORT can be decreased when combined with Aluminium.


The bioavailability of flurandrenolide can be decreased when combined with Almasilate.


The bioavailability of medrysone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of fludrocortisone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of alclometasone can be decreased when combined with Almasilate.


The bioavailability of Estrone sulfate can be decreased when combined with Magaldrate.


The bioavailability of halcinonide can be decreased when combined with Magaldrate.


The bioavailability of difluprednate can be decreased when combined with Magaldrate.


The bioavailability of DEFLAZACORT can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Fluprednidene can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of dexamethasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of fluocinonide can be decreased when combined with Aluminium.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with Magaldrate.


The bioavailability of flumethasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of methylprednisolone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of RIMEXOLONE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of loteprednol can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with Aluminium.


The bioavailability of Halobetasol can be decreased when combined with Aluminium.


The bioavailability of estrone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of loteprednol can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of triamcinolone can be decreased when combined with Almasilate.


The bioavailability of Fluprednidene can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of FLUOCORTOLONE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of fluocinonide can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of PREDNICARBATE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of amcinonide can be decreased when combined with Trometamol.


The bioavailability of formestane can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of Fluticasone furoate can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of CORTISONE ACETATE can be decreased when combined with Magaldrate.


The bioavailability of Mometasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of paramethasone can be decreased when combined with Magaldrate.


The bioavailability of alclometasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of DESONIDE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with Magnesium trisilicate.


The bioavailability of estrone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of equilin can be decreased when combined with Magaldrate.


The bioavailability of amcinonide can be decreased when combined with Aluminium.


The bioavailability of Clobetasone can be decreased when combined with Aluminium.


The bioavailability of medrysone can be decreased when combined with Magnesium trisilicate.


The bioavailability of equilin can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of CORTISONE ACETATE can be decreased when combined with Magnesium trisilicate.


The bioavailability of RIMEXOLONE can be decreased when combined with Aluminium hydroxide.


The bioavailability of paramethasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of triamcinolone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of budesonide can be decreased when combined with Aluminium.


The bioavailability of budesonide can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of CLOCORTOLONE can be decreased when combined with Almasilate.


The bioavailability of CORTISONE ACETATE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of paramethasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of methylprednisolone can be decreased when combined with Magnesium trisilicate.


The bioavailability of medrysone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Mometasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of amcinonide can be decreased when combined with Almasilate.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with Magaldrate.


The bioavailability of diflorasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of triamcinolone can be decreased when combined with Trometamol.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of estrone can be decreased when combined with Magnesium trisilicate.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with Aluminium hydroxide.


The bioavailability of Clobetasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of prednisone can be decreased when combined with Magaldrate.


The bioavailability of methylprednisolone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of desoximetasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of fluocinonide can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of fluocinonide can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of triamcinolone can be decreased when combined with Aluminium hydroxide.


The bioavailability of CLOCORTOLONE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of prednisone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of diflorasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of betamethasone can be decreased when combined with Magaldrate.


The bioavailability of prednisone can be decreased when combined with Aluminium hydroxide.


The bioavailability of flurandrenolide can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of dexamethasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of methylprednisolone can be decreased when combined with Almasilate.


The bioavailability of CLOCORTOLONE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of methylprednisolone can be decreased when combined with Aluminium.


The bioavailability of alclometasone can be decreased when combined with Trometamol.


The bioavailability of loteprednol can be decreased when combined with Magaldrate.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with Aluminium.


The bioavailability of equilin can be decreased when combined with Aluminium hydroxide.


The bioavailability of budesonide can be decreased when combined with Magaldrate.


The bioavailability of budesonide can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of equilin can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of estrone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of dexamethasone can be decreased when combined with Magaldrate.


The bioavailability of flurandrenolide can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of flumethasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of Mometasone can be decreased when combined with Trometamol.


The bioavailability of estrone can be decreased when combined with Almasilate.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with Aluminium.


The bioavailability of medrysone can be decreased when combined with Aluminium.


The bioavailability of fludrocortisone can be decreased when combined with Magnesium trisilicate.


The bioavailability of PREDNICARBATE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of flumethasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of loteprednol can be decreased when combined with Aluminium hydroxide.


The bioavailability of Fluprednidene can be decreased when combined with Trometamol.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with Trometamol.


The bioavailability of betamethasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of hydrocortisone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of equilin can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of Mometasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of triamcinolone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Estrone sulfate can be decreased when combined with Aluminium hydroxide.


The bioavailability of flunisolide can be decreased when combined with Magnesium trisilicate.


The bioavailability of desoximetasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of flumethasone can be decreased when combined with Trometamol.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of fluocinonide can be decreased when combined with Trometamol.


The bioavailability of Ciclesonide can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of diflorasone can be decreased when combined with Almasilate.


The bioavailability of betamethasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of alclometasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of loteprednol can be decreased when combined with Almasilate.


The bioavailability of hydrocortisone can be decreased when combined with Magaldrate.


The bioavailability of DEFLAZACORT can be decreased when combined with Magnesium trisilicate.


The bioavailability of flunisolide can be decreased when combined with Magaldrate.


The bioavailability of DESONIDE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Fluprednidene can be decreased when combined with Almasilate.


The bioavailability of FLUOCORTOLONE can be decreased when combined with Almasilate.


The bioavailability of Clobetasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of amcinonide can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of fludrocortisone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of DESONIDE can be decreased when combined with Almasilate.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with Almasilate.


The bioavailability of CLOCORTOLONE can be decreased when combined with Magaldrate.


The bioavailability of RIMEXOLONE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of DEFLAZACORT can be decreased when combined with Almasilate.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of halcinonide can be decreased when combined with Aluminium hydroxide.


The bioavailability of difluprednate can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of Ciclesonide can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of halcinonide can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of difluprednate can be decreased when combined with Aluminium hydroxide.


The bioavailability of flurandrenolide can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of alclometasone can be decreased when combined with Magaldrate.


The bioavailability of formestane can be decreased when combined with Almasilate.


The bioavailability of Mometasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of PREDNICARBATE can be decreased when combined with Trometamol.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of Mometasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of DESONIDE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of flurandrenolide can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of betamethasone can be decreased when combined with Trometamol.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of flurandrenolide can be decreased when combined with Magaldrate.


The bioavailability of Fluticasone furoate can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of formestane can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of fludrocortisone can be decreased when combined with Aluminium.


The bioavailability of equilin can be decreased when combined with Trometamol.


The bioavailability of FLUOCORTOLONE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Fluprednidene can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Tixocortol can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of flunisolide can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of equilin can be decreased when combined with Aluminium.


The bioavailability of flumethasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with Aluminium hydroxide.


The bioavailability of halcinonide can be decreased when combined with Trometamol.


The bioavailability of desoximetasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Ciclesonide can be decreased when combined with Trometamol.


The bioavailability of CORTISONE ACETATE can be decreased when combined with Aluminium hydroxide.


The bioavailability of alclometasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of paramethasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of DEFLAZACORT can be decreased when combined with Magaldrate.


The bioavailability of DESONIDE can be decreased when combined with Magaldrate.


The bioavailability of Mometasone can be decreased when combined with Almasilate.


The bioavailability of flurandrenolide can be decreased when combined with Trometamol.


The bioavailability of Ciclesonide can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of loteprednol can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of fludrocortisone can be decreased when combined with Almasilate.


The bioavailability of dexamethasone can be decreased when combined with Aluminium.


The bioavailability of dexamethasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of amcinonide can be decreased when combined with Magnesium trisilicate.


The bioavailability of paramethasone can be decreased when combined with Trometamol.


The bioavailability of CORTISONE ACETATE can be decreased when combined with Trometamol.


The bioavailability of flurandrenolide can be decreased when combined with Aluminium hydroxide.


The bioavailability of amcinonide can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of RIMEXOLONE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of alclometasone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of equilin can be decreased when combined with Magnesium trisilicate.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with Trometamol.


The bioavailability of DEFLAZACORT can be decreased when combined with Trometamol.


The bioavailability of desoximetasone can be decreased when combined with Almasilate.


The bioavailability of fluocinonide can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of CLOCORTOLONE can be decreased when combined with Aluminium hydroxide.


The bioavailability of desoximetasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of estrone can be decreased when combined with Trometamol.


The bioavailability of Ciclesonide can be decreased when combined with Magaldrate.


The bioavailability of Estrone sulfate can be decreased when combined with Trometamol.


The bioavailability of triamcinolone can be decreased when combined with Magnesium trisilicate.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of budesonide can be decreased when combined with Almasilate.


The bioavailability of paramethasone can be decreased when combined with Almasilate.


The bioavailability of CORTISONE ACETATE can be decreased when combined with Almasilate.


The bioavailability of Estrone sulfate can be decreased when combined with Magnesium trisilicate.


The bioavailability of PREDNICARBATE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of RIMEXOLONE can be decreased when combined with Magnesium trisilicate.


The bioavailability of amcinonide can be decreased when combined with Magaldrate.


The bioavailability of Fluticasone furoate can be decreased when combined with Aluminium hydroxide.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with Almasilate.


The bioavailability of PREDNICARBATE can be decreased when combined with Magaldrate.


The bioavailability of difluprednate can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of methylprednisolone can be decreased when combined with Magaldrate.


The bioavailability of halcinonide can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of dexamethasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of budesonide can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Tixocortol can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Clobetasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of budesonide can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of betamethasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of CORTISONE ACETATE can be decreased when combined with Aluminium.


The bioavailability of Estrone sulfate can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of paramethasone can be decreased when combined with Aluminium.


The bioavailability of FLUOCORTOLONE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of Tixocortol can be decreased when combined with Almasilate.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Ciclesonide can be decreased when combined with Aluminium.


The bioavailability of equilin can be decreased when combined with Almasilate.


The bioavailability of Estrone sulfate can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of loteprednol can be decreased when combined with Trometamol.


The bioavailability of flumethasone can be decreased when combined with Aluminium.


The bioavailability of Fluticasone furoate can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of fludrocortisone can be decreased when combined with Magaldrate.


The bioavailability of loteprednol can be decreased when combined with Magnesium trisilicate.


The bioavailability of prednisone can be decreased when combined with Aluminium.


The bioavailability of flunisolide can be decreased when combined with Trometamol.


The bioavailability of amcinonide can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of flumethasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of FLUOCORTOLONE can be decreased when combined with Aluminium.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of estrone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with Aluminium.


The bioavailability of Tixocortol can be decreased when combined with Aluminium hydroxide.


The bioavailability of alclometasone can be decreased when combined with Aluminium.


The bioavailability of CLOCORTOLONE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of alclometasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Fluticasone furoate can be decreased when combined with Trometamol.


The bioavailability of formestane can be decreased when combined with Trometamol.


The bioavailability of flunisolide can be decreased when combined with Aluminium.


The bioavailability of hydrocortisone can be decreased when combined with Aluminium hydroxide.


The bioavailability of Halobetasol can be decreased when combined with Trometamol.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with Trometamol.


The bioavailability of flunisolide can be decreased when combined with Aluminium hydroxide.


The bioavailability of fluocinonide can be decreased when combined with Aluminium hydroxide.


The bioavailability of Halobetasol can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with Almasilate.


The bioavailability of difluprednate can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with Almasilate.


The bioavailability of halcinonide can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of Ciclesonide can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of equilin can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of Fluticasone furoate can be decreased when combined with Aluminium.


The bioavailability of formestane can be decreased when combined with Aluminium.


The bioavailability of hydrocortisone can be decreased when combined with Aluminium.


The bioavailability of betamethasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of alclometasone can be decreased when combined with Aluminium hydroxide.


The bioavailability of CORTISONE ACETATE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of desoximetasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of medrysone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of fludrocortisone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of flunisolide can be decreased when combined with Almasilate.


The bioavailability of fludrocortisone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Mometasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of budesonide can be decreased when combined with Trometamol.


The bioavailability of halcinonide can be decreased when combined with Aluminium.


The bioavailability of estrone can be decreased when combined with Magaldrate.


The bioavailability of difluprednate can be decreased when combined with Aluminium.


The bioavailability of Dehydroepiandrosterone can be decreased when combined with Magaldrate.


The bioavailability of DESONIDE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Fluprednidene can be decreased when combined with Magaldrate.


The bioavailability of methylprednisolone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of methylprednisolone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of RIMEXOLONE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of Halobetasol can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of formestane can be decreased when combined with Aluminium hydroxide.


The bioavailability of medrysone can be decreased when combined with Magaldrate.


The bioavailability of loteprednol can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of FLUOCORTOLONE can be decreased when combined with Trometamol.


The bioavailability of halcinonide can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of Estrone sulfate can be decreased when combined with Aluminium.


The bioavailability of DEFLAZACORT can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Clobetasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of prednisone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of loteprednol can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of Clobetasone can be decreased when combined with Almasilate.


The bioavailability of DESONIDE can be decreased when combined with Aluminium hydroxide.


The bioavailability of triamcinolone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of hydrocortisone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with Magnesium trisilicate.


The bioavailability of difluprednate can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of FLUOCORTOLONE can be decreased when combined with Aluminium hydroxide.


The bioavailability of Fluprednidene can be decreased when combined with Aluminium hydroxide.


The bioavailability of diflorasone can be decreased when combined with Magaldrate.


The bioavailability of betamethasone can be decreased when combined with Aluminium.


The bioavailability of CLOCORTOLONE can be decreased when combined with Aluminium.


The bioavailability of estrone can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of dexamethasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of estrone can be decreased when combined with Aluminium.


The bioavailability of Ciclesonide can be decreased when combined with Aluminium hydroxide.


The bioavailability of Fluprednidene can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of FLUOCORTOLONE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of CLOBETASOL PROPIONATE can be decreased when combined with Trometamol.


The bioavailability of fludrocortisone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of Clobetasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of desoximetasone can be decreased when combined with Trometamol.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with Trometamol.


The bioavailability of CLOCORTOLONE can be decreased when combined with Trometamol.


The bioavailability of triamcinolone can be decreased when combined with Aluminium.


The bioavailability of Estrone sulfate can be decreased when combined with Almasilate.


The bioavailability of amcinonide can be decreased when combined with Aluminium hydroxide.


The bioavailability of CLOCORTOLONE can be decreased when combined with Magnesium trisilicate.


The bioavailability of FLUTICASONE PROPIONATE can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of atenolol can be decreased when combined with ampicillin.


The bioavailability of hydrocortisone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of hydrocortisone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of PREDNICARBATE can be decreased when combined with Aluminium hydroxide.


The bioavailability of Fluprednidene can be decreased when combined with Aluminium.


The bioavailability of triamcinolone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of DESONIDE can be decreased when combined with Trometamol.


The bioavailability of Ciclesonide can be decreased when combined with Almasilate.


The bioavailability of PREDNICARBATE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of Fluticasone furoate can be decreased when combined with Almasilate.


The bioavailability of prednisone can be decreased when combined with Magnesium trisilicate.


The bioavailability of hydrocortisone can be decreased when combined with Magnesium trisilicate.


The bioavailability of Tixocortol can be decreased when combined with Trometamol.


The bioavailability of dexamethasone can be decreased when combined with Almasilate.


The bioavailability of BECLOMETHASONE DIPROPIONATE can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of flurandrenolide can be decreased when combined with Magnesium trisilicate.


The bioavailability of CLOCORTOLONE can be decreased when combined with SODIUM BICARBONATE.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with Magnesium trisilicate.


The bioavailability of Halobetasol can be decreased when combined with Magnesium trisilicate.


The bioavailability of diflorasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of Fluprednidene can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of FLUOCORTOLONE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of Mometasone can be decreased when combined with Aluminium.


The bioavailability of paramethasone can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of betamethasone can be decreased when combined with Magnesium trisilicate.


The bioavailability of Clobetasone can be decreased when combined with Magaldrate.


The bioavailability of medrysone can be decreased when combined with Almasilate.


The bioavailability of Tixocortol can be decreased when combined with Magaldrate.


The bioavailability of fluocinonide can be decreased when combined with Almasilate.


The bioavailability of Ciclesonide can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of CLOCORTOLONE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of budesonide can be decreased when combined with Aluminium hydroxide.


The bioavailability of flumethasone can be decreased when combined with Magaldrate.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with MAGNESIUM OXIDE.


The bioavailability of dexamethasone can be decreased when combined with Bismuth subcitrate potassium.


The bioavailability of diflorasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of budesonide can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of flurandrenolide can be decreased when combined with Aluminium.


The bioavailability of Fluticasone furoate can be decreased when combined with Magnesium trisilicate.


The bioavailability of flumethasone can be decreased when combined with MAGNESIUM HYDROXIDE.


The bioavailability of formestane can be decreased when combined with Magnesium trisilicate.


The bioavailability of CORTISONE ACETATE can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of paramethasone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of loteprednol can be decreased when combined with Aluminium.


The bioavailability of medrysone can be decreased when combined with CALCIUM CARBONATE.


The bioavailability of FLUOCINOLONE ACETONIDE can be decreased when combined with Magaldrate.


The bioavailability of Halobetasol can be decreased when combined with Magaldrate.


The bioavailability of flurandrenolide can be decreased when combined with CALCIUM CARBONATE.


The metabolism of antipyrine can be increased when combined with RIFABUTIN.


The metabolism of erythromycin can be increased when combined with phenytoin.


The metabolism of dorzolamide can be increased when combined with RIFABUTIN.


The metabolism of barnidipine can be increased when combined with thiamylal.


The metabolism of Aceclofenac can be increased when combined with Rifampicin.


The metabolism of benzphetamine can be increased when combined with RIFABUTIN.


The metabolism of benzyl alcohol can be increased when combined with Fosphenytoin.


The metabolism of CABAZITAXEL can be increased when combined with Fosphenytoin.


The metabolism of chenodeoxycholic acid can be increased when combined with Fosphenytoin.


The metabolism of Vardenafil can be increased when combined with RIFABUTIN.


The metabolism of Ruxolitinib can be increased when combined with phenytoin.


The metabolism of Fluticasone furoate can be increased when combined with carbamazepine.


The metabolism of nicardipine can be increased when combined with nafcillin.


The metabolism of Pipotiazine can be increased when combined with Fosphenytoin.


The metabolism of Copanlisib can be increased when combined with carbamazepine.


The metabolism of zidovudine can be increased when combined with primidone.


The metabolism of oxycodone can be increased when combined with primidone.


The metabolism of zaltoprofen can be increased when combined with Rifampicin.


The metabolism of loperamide can be increased when combined with phenobarbital.


The metabolism of Ambrisentan can be increased when combined with Rifampicin.


The metabolism of phenindione can be increased when combined with primidone.


The metabolism of flutamide can be increased when combined with primidone.


The metabolism of tretinoin can be increased when combined with pentobarbital.


The metabolism of TASOSARTAN can be increased when combined with nevirapine.


The metabolism of trazodone can be increased when combined with primidone.


The metabolism of Tiotropium can be increased when combined with phenobarbital.


The metabolism of estrone can be increased when combined with primidone.


The metabolism of Dehydroepiandrosterone can be increased when combined with primidone.


The metabolism of Rupatadine can be increased when combined with RIFAPENTINE.


The metabolism of doxorubicin can be increased when combined with RIFAPENTINE.


The metabolism of oxaprozin can be increased when combined with RIFAPENTINE.


The metabolism of benzyl alcohol can be increased when combined with pentobarbital.


The metabolism of Tramadol can be increased when combined with pentobarbital.


The metabolism of ergocalciferol can be increased when combined with nevirapine.


The metabolism of indapamide can be increased when combined with Fosphenytoin.


The metabolism of estrone can be increased when combined with carbamazepine.


The metabolism of DIHYDROCODEINE can be increased when combined with Rifampicin.


The metabolism of trazodone can be increased when combined with carbamazepine.


The metabolism of Lacidipine can be increased when combined with pentobarbital.


The metabolism of lansoprazole can be increased when combined with pentobarbital.


The metabolism of erythromycin can be increased when combined with pentobarbital.


The metabolism of CABAZITAXEL can be increased when combined with pentobarbital.


The metabolism of bromazepam can be increased when combined with Rifampicin.


The metabolism of clotiazepam can be increased when combined with Rifampicin.


The metabolism of CABAZITAXEL can be increased when combined with carbamazepine.


The metabolism of Vismodegib can be increased when combined with Rifampicin.


The metabolism of bepridil can be increased when combined with nafcillin.


The metabolism of Levomilnacipran can be increased when combined with nevirapine.


The metabolism of cyclobenzaprine can be increased when combined with Mephobarbital.


The metabolism of Iloperidone can be increased when combined with pentobarbital.


The metabolism of cyclosporin A can be increased when combined with amobarbital.


The metabolism of ondansetron can be increased when combined with phenobarbital.


The metabolism of cocaine can be increased when combined with phenobarbital.


The metabolism of tiagabine can be increased when combined with phenobarbital.


The metabolism of ketamine can be increased when combined with primidone.


The metabolism of oxybutynin can be increased when combined with pentobarbital.


The metabolism of tetracycline can be increased when combined with phenytoin.


The metabolism of Dehydroepiandrosterone can be increased when combined with Rifampicin.


The metabolism of Levocetirizine can be increased when combined with Rifampicin.


The metabolism of Lapatinib can be increased when combined with secobarbital.


The metabolism of IDARUBICIN can be increased when combined with carbamazepine.


The metabolism of Pomalidomide can be increased when combined with Rifampicin.


The metabolism of donepezil can be increased when combined with primidone.


The metabolism of busulfan can be increased when combined with RIFAPENTINE.


The metabolism of ketoprofen can be increased when combined with RIFAPENTINE.


The metabolism of Paritaprevir can be increased when combined with RIFAPENTINE.


The metabolism of Velpatasvir can be increased when combined with pentobarbital.


The metabolism of Levobupivacaine can be increased when combined with RIFAPENTINE.


The metabolism of raloxifene can be increased when combined with phenytoin.


The metabolism of letrozole can be increased when combined with RIFAPENTINE.


The metabolism of Azelnidipine can be increased when combined with primidone.


The metabolism of warfarin can be increased when combined with Rifaximin.


The metabolism of letrozole can be increased when combined with nevirapine.


The metabolism of TASOSARTAN can be increased when combined with Fosphenytoin.


The metabolism of eperisone can be increased when combined with primidone.


The metabolism of nortriptyline can be increased when combined with amobarbital.


The metabolism of Mephobarbital can be increased when combined with pyridoxine.


The metabolism of cephalexin can be increased when combined with phenytoin.


The metabolism of amoxapine can be increased when combined with amobarbital.


The metabolism of zaltoprofen can be increased when combined with Aprepitant.


The metabolism of Aceclofenac can be increased when combined with Aprepitant.


The metabolism of atorvastatin can be increased when combined with Bosentan.


The metabolism of Bortezomib can be increased when combined with secobarbital.


The metabolism of acetaminophen can be increased when combined with thiamylal.


The metabolism of oxazepam can be increased when combined with carbamazepine.


The metabolism of Yohimbine can be increased when combined with Rifampicin.


The metabolism of desipramine can be increased when combined with amobarbital.


The metabolism of cyclosporin A can be increased when combined with secobarbital.


The metabolism of digitoxin can be increased when combined with Rifampicin.


The metabolism of 5-Fluorouracil can be increased when combined with secobarbital.


The metabolism of zafirlukast can be increased when combined with secobarbital.


The metabolism of salicylic acid can be increased when combined with secobarbital.


The metabolism of Mirabegron can be increased when combined with phenytoin.


The metabolism of nimesulide can be increased when combined with pentobarbital.


The metabolism of valsartan can be increased when combined with phenytoin.


The metabolism of Tianeptine can be increased when combined with METHOHEXITAL.


The metabolism of Lumefantrine can be increased when combined with primidone.


The metabolism of cyclophosphamide can be increased when combined with pentobarbital.


The metabolism of orphenadrine can be increased when combined with Rifampicin.


The metabolism of ritonavir can be increased when combined with carbamazepine.


The metabolism of haloperidol can be increased when combined with carbamazepine.


The metabolism of Pinaverium can be increased when combined with nafcillin.


The metabolism of Dehydroepiandrosterone can be increased when combined with RIFAPENTINE.


The metabolism of bromocriptine can be increased when combined with nevirapine.


The metabolism of carvedilol can be increased when combined with RIFAPENTINE.


The metabolism of cytarabine can be increased when combined with Fosphenytoin.


The metabolism of Ramelteon can be increased when combined with Fosphenytoin.


The metabolism of proguanil can be increased when combined with RIFAPENTINE.


The metabolism of Pioglitazone can be increased when combined with RIFAPENTINE.


The metabolism of formoterol can be increased when combined with Fosphenytoin.


The metabolism of ipratropium can be increased when combined with nevirapine.


The metabolism of buspirone can be increased when combined with primidone.


The metabolism of antipyrine can be increased when combined with phenobarbital.


The metabolism of sulfinpyrazone can be increased when combined with RIFAPENTINE.


The metabolism of tiagabine can be increased when combined with pentobarbital.


The metabolism of spiramycin can be increased when combined with phenytoin.


The metabolism of SERTINDOLE can be increased when combined with phenytoin.


The metabolism of indomethacin can be increased when combined with secobarbital.


The metabolism of flunitrazepam can be increased when combined with secobarbital.


The metabolism of hydromorphone can be increased when combined with secobarbital.


The metabolism of naloxone can be increased when combined with phenobarbital.


The metabolism of amitriptyline can be increased when combined with secobarbital.


The metabolism of galanthamine can be increased when combined with Lumacaftor.


The metabolism of allylestrenol can be increased when combined with carbamazepine.


The metabolism of Ruxolitinib can be increased when combined with RIFABUTIN.


The metabolism of antipyrine can be increased when combined with carbamazepine.


The metabolism of indinavir can be increased when combined with pentobarbital.


The metabolism of lovastatin can be increased when combined with pentobarbital.


The metabolism of pilocarpine can be increased when combined with Rifampicin.


The metabolism of doxorubicin can be increased when combined with pentobarbital.


The metabolism of nelfinavir can be increased when combined with pentobarbital.


The metabolism of prochlorperazine can be increased when combined with carbamazepine.


The metabolism of metronidazole can be increased when combined with secobarbital.


The metabolism of Halofantrine can be increased when combined with carbamazepine.


The metabolism of dantrolene can be increased when combined with carbamazepine.


The metabolism of barnidipine can be increased when combined with pentobarbital.


The metabolism of Tramadol can be increased when combined with RIFAPENTINE.


The metabolism of Melatonin can be increased when combined with primidone.


The metabolism of erythromycin can be increased when combined with RIFAPENTINE.


The metabolism of estazolam can be increased when combined with carbamazepine.


The metabolism of chlorzoxazone can be increased when combined with RIFAPENTINE.


The metabolism of alfuzosin can be increased when combined with carbamazepine.


The metabolism of protriptyline can be increased when combined with carbamazepine.


The metabolism of propofol can be increased when combined with primidone.


The metabolism of chlorpheniramine can be increased when combined with nevirapine.


The metabolism of Tianeptine can be increased when combined with primidone.


The metabolism of miconazole can be increased when combined with nevirapine.


The metabolism of sulfadiazine can be increased when combined with RIFAPENTINE.


The metabolism of mefloquine can be increased when combined with RIFAPENTINE.


The metabolism of Levobupivacaine can be increased when combined with Fosphenytoin.


The metabolism of Lornoxicam can be increased when combined with primidone.


The metabolism of budesonide can be increased when combined with RIFAPENTINE.


The metabolism of zolpidem can be increased when combined with nevirapine.


The metabolism of letrozole can be increased when combined with Fosphenytoin.


The metabolism of promazine can be increased when combined with nevirapine.


The metabolism of dienestrol can be increased when combined with griseofulvin.


The metabolism of dexlansoprazole can be increased when combined with nevirapine.


The metabolism of ketoprofen can be increased when combined with Fosphenytoin.


The metabolism of diphenhydramine can be increased when combined with primidone.


The metabolism of PERHEXILINE can be increased when combined with primidone.


The metabolism of atorvastatin can be increased when combined with primidone.


The metabolism of dolasetron can be increased when combined with phenytoin.


The metabolism of Mephobarbital can be increased when combined with Rifaximin.


The metabolism of amobarbital can be increased when combined with pyridoxine.


The metabolism of tolbutamide can be increased when combined with secobarbital.


The metabolism of Hexobarbital can be increased when combined with pyridoxine.


The metabolism of ethinyl estradiol can be increased when combined with primidone.


The metabolism of IMIQUIMOD can be increased when combined with phenytoin.


The metabolism of allylestrenol can be increased when combined with primidone.


The metabolism of Lenvatinib can be increased when combined with pentobarbital.


The metabolism of primidone can be increased when combined with phenytoin.


The metabolism of tazarotene can be increased when combined with primidone.


The metabolism of Candesartan cilexetil can be increased when combined with phenytoin.


The metabolism of vinorelbine can be increased when combined with carbamazepine.


The metabolism of Aliskiren can be increased when combined with RIFAPENTINE.


The metabolism of fluvastatin can be increased when combined with RIFABUTIN.


The metabolism of LISURIDE can be increased when combined with phenobarbital.


The metabolism of FLUTICASONE PROPIONATE can be increased when combined with phenobarbital.


The metabolism of allylestrenol can be increased when combined with nevirapine.


The metabolism of Reboxetine can be increased when combined with phenobarbital.


The metabolism of trimipramine can be increased when combined with RIFABUTIN.


The metabolism of Almotriptan can be increased when combined with secobarbital.


The metabolism of temazepam can be increased when combined with phenobarbital.


The metabolism of alclometasone can be increased when combined with Lumacaftor.


The metabolism of niclosamide can be increased when combined with carbamazepine.


The metabolism of dapsone can be increased when combined with primidone.


The metabolism of lovastatin can be increased when combined with Bosentan.


The metabolism of enalapril can be increased when combined with phenobarbital.


The metabolism of Ziprasidone can be increased when combined with Lumacaftor.


The metabolism of nevirapine can be increased when combined with phenobarbital.


The metabolism of promethazine can be increased when combined with nevirapine.


The metabolism of rabeprazole can be increased when combined with Rifampicin.


The metabolism of rabeprazole can be increased when combined with RIFABUTIN.


The metabolism of spiramycin can be increased when combined with Rifampicin.


The metabolism of dexlansoprazole can be increased when combined with primidone.


The metabolism of nicotine can be increased when combined with nevirapine.


The metabolism of thiopental can be increased when combined with pyridoxine.


The metabolism of podophyllotoxin can be increased when combined with Fosphenytoin.


The metabolism of Permethrin can be increased when combined with Rifampicin.


The metabolism of IDARUBICIN can be increased when combined with Fosphenytoin.


The metabolism of Enasidenib can be increased when combined with RIFAPENTINE.


The metabolism of Escitalopram can be increased when combined with Fosphenytoin.


The metabolism of Propoxyphene napsylate can be increased when combined with RIFABUTIN.


The metabolism of glipizide can be increased when combined with nevirapine.


The metabolism of moclobemide can be increased when combined with Fosphenytoin.


The metabolism of oxymorphone can be increased when combined with nevirapine.


The metabolism of nilutamide can be increased when combined with phenytoin.


The metabolism of Permethrin can be increased when combined with phenobarbital.


The metabolism of nitrendipine can be increased when combined with secobarbital.


The metabolism of SERTINDOLE can be increased when combined with pentobarbital.


The metabolism of spiramycin can be increased when combined with pentobarbital.


The metabolism of Ospemifene can be increased when combined with phenobarbital.


The metabolism of salicylic acid can be increased when combined with primidone.


The metabolism of acetaminophen can be increased when combined with METHOHEXITAL.


The metabolism of ipratropium can be increased when combined with Rifampicin.


The metabolism of nicardipine can be increased when combined with Rifampicin.


The metabolism of Pimecrolimus can be increased when combined with Rifampicin.


The metabolism of testosterone can be increased when combined with Rifampicin.


The metabolism of trimethoprim can be increased when combined with pentobarbital.


The metabolism of ibuprofen can be increased when combined with phenobarbital.


The metabolism of clorazepate can be increased when combined with Rifampicin.


The metabolism of prazepam can be increased when combined with phenobarbital.


The metabolism of nitrendipine can be increased when combined with phenobarbital.


The metabolism of Imidafenacin can be increased when combined with nevirapine.


The metabolism of roxithromycin can be increased when combined with RIFAPENTINE.


The metabolism of Elvitegravir can be increased when combined with pentobarbital.


The metabolism of Fingolimod can be increased when combined with Lumacaftor.


The metabolism of PARAMETHADIONE can be increased when combined with RIFABUTIN.


The metabolism of ACENOCOUMAROL can be increased when combined with thiamylal.


The metabolism of oxybutynin can be increased when combined with nevirapine.


The metabolism of BISOPROLOL can be increased when combined with RIFABUTIN.


The metabolism of Udenafil can be increased when combined with nevirapine.


The metabolism of astemizole can be increased when combined with nevirapine.


The metabolism of clofibrate can be increased when combined with nevirapine.


The metabolism of desipramine can be increased when combined with primidone.


The metabolism of isoflurane can be increased when combined with carbamazepine.


The metabolism of Fosamprenavir can be increased when combined with RIFAPENTINE.


The metabolism of valsartan can be increased when combined with RIFAPENTINE.


The metabolism of Lumiracoxib can be increased when combined with primidone.


The metabolism of pravastatin can be increased when combined with RIFAPENTINE.


The metabolism of bicalutamide can be increased when combined with RIFABUTIN.


The metabolism of desipramine can be increased when combined with thiopental.


The metabolism of estradiol can be increased when combined with griseofulvin.


The metabolism of epinastine can be increased when combined with Fosphenytoin.


The metabolism of sevoflurane can be increased when combined with RIFABUTIN.


The metabolism of isoflurane can be increased when combined with Fosphenytoin.


The metabolism of tretinoin can be increased when combined with Fosphenytoin.


The metabolism of phenoxybenzamine can be increased when combined with phenytoin.


The metabolism of dolasetron can be increased when combined with Fosphenytoin.


The metabolism of Neratinib can be increased when combined with Fosphenytoin.


The metabolism of tetracycline can be increased when combined with Fosphenytoin.


The metabolism of docetaxel can be increased when combined with Fosphenytoin.


The metabolism of spiramycin can be increased when combined with primidone.


The metabolism of cyclobenzaprine can be increased when combined with phenytoin.


The metabolism of tetracycline can be increased when combined with Rifampicin.


The metabolism of KETAZOLAM can be increased when combined with RIFABUTIN.


The metabolism of clonidine can be increased when combined with phenytoin.


The metabolism of Pimecrolimus can be increased when combined with phenytoin.


The metabolism of nicotine can be increased when combined with RIFABUTIN.


The metabolism of Cevimeline can be increased when combined with RIFABUTIN.


The metabolism of ipratropium can be increased when combined with phenytoin.


The metabolism of Salmeterol can be increased when combined with Rifampicin.


The metabolism of flunisolide can be increased when combined with RIFABUTIN.


The metabolism of cabergoline can be increased when combined with Rifampicin.


The metabolism of Ximelagatran can be increased when combined with primidone.


The metabolism of Ziprasidone can be increased when combined with Rifampicin.


The metabolism of benztropine can be increased when combined with Rifampicin.


The metabolism of salicylic acid can be increased when combined with Rifampicin.


The metabolism of Etoricoxib can be increased when combined with pentobarbital.


The metabolism of alclometasone can be increased when combined with Rifampicin.


The metabolism of BISOPROLOL can be increased when combined with RIFAPENTINE.


The metabolism of amodiaquine can be increased when combined with RIFAPENTINE.


The metabolism of PARAMETHADIONE can be increased when combined with RIFAPENTINE.


The metabolism of Dothiepin can be increased when combined with primidone.


The metabolism of RIFABUTIN can be increased when combined with RIFAPENTINE.


The metabolism of histamine can be increased when combined with primidone.


The metabolism of Almotriptan can be increased when combined with nevirapine.


The metabolism of pergolide can be increased when combined with phenobarbital.


The metabolism of Dehydroepiandrosterone can be increased when combined with phenobarbital.


The metabolism of domperidone can be increased when combined with phenobarbital.


The metabolism of quazepam can be increased when combined with RIFAPENTINE.


The metabolism of estazolam can be increased when combined with Lumacaftor.


The metabolism of finasteride can be increased when combined with Lumacaftor.


The metabolism of haloperidol can be increased when combined with RIFABUTIN.


The metabolism of dantrolene can be increased when combined with Lumacaftor.


The metabolism of KETAZOLAM can be increased when combined with RIFAPENTINE.


The metabolism of valsartan can be increased when combined with Aprepitant.


The metabolism of montelukast can be increased when combined with phenytoin.


The metabolism of cabergoline can be increased when combined with phenytoin.


The metabolism of mefenamic acid can be increased when combined with Fosphenytoin.


The metabolism of nitrendipine can be increased when combined with RIFABUTIN.


The metabolism of alclometasone can be increased when combined with phenytoin.


The metabolism of Ziprasidone can be increased when combined with phenytoin.


The metabolism of bupivacaine can be increased when combined with RIFABUTIN.


The metabolism of ETONOGESTREL can be increased when combined with RIFABUTIN.


The metabolism of benztropine can be increased when combined with phenytoin.


The metabolism of RANOLAZINE can be increased when combined with Fosphenytoin.


The metabolism of ACENOCOUMAROL can be increased when combined with glutethimide.


The metabolism of alclometasone can be increased when combined with Fosphenytoin.


The metabolism of Levocetirizine can be increased when combined with RIFAPENTINE.


The metabolism of Ziprasidone can be increased when combined with Fosphenytoin.


The metabolism of benztropine can be increased when combined with Fosphenytoin.


The metabolism of RUCAPARIB can be increased when combined with phenobarbital.


The metabolism of Docosahexaenoic acid can be increased when combined with primidone.


The metabolism of Pinaverium can be increased when combined with amobarbital.


The metabolism of cabergoline can be increased when combined with Fosphenytoin.


The metabolism of granisetron can be increased when combined with Lumacaftor.


The metabolism of indapamide can be increased when combined with Rifampicin.


The metabolism of PHENPROCOUMON can be increased when combined with glutethimide.


The metabolism of PERHEXILINE can be increased when combined with pentobarbital.


The metabolism of dexlansoprazole can be increased when combined with Fosphenytoin.


The metabolism of haloperidol can be increased when combined with RIFAPENTINE.


The metabolism of ritonavir can be increased when combined with RIFAPENTINE.


The metabolism of oxymorphone can be increased when combined with phenobarbital.


The metabolism of norethindrone can be increased when combined with primidone.


The metabolism of Cariprazine can be increased when combined with carbamazepine.


The metabolism of flurbiprofen can be increased when combined with primidone.


The metabolism of Venetoclax can be increased when combined with phenobarbital.


The metabolism of aminophylline can be increased when combined with RIFAPENTINE.


The metabolism of thiotepa can be increased when combined with nevirapine.


The metabolism of METHOHEXITAL can be increased when combined with RIFABUTIN.


The metabolism of chlordiazepoxide can be increased when combined with RIFABUTIN.


The metabolism of fluoxetine can be increased when combined with RIFABUTIN.


The metabolism of Vilanterol can be increased when combined with phenobarbital.


The metabolism of montelukast can be increased when combined with RIFABUTIN.


The metabolism of terbinafine can be increased when combined with nevirapine.


The metabolism of mianserin can be increased when combined with RIFAPENTINE.


The metabolism of Eszopiclone can be increased when combined with Fosphenytoin.


The metabolism of prazepam can be increased when combined with nevirapine.


The metabolism of Deutetrabenazine can be increased when combined with carbamazepine.


The metabolism of thiotepa can be increased when combined with RIFABUTIN.


The metabolism of colchicine can be increased when combined with phenytoin.


The metabolism of loratadine can be increased when combined with secobarbital.


The metabolism of Estrone sulfate can be increased when combined with RIFABUTIN.


The metabolism of Brigatinib can be increased when combined with nevirapine.


The metabolism of cinnarizine can be increased when combined with secobarbital.


The metabolism of rapamycin can be increased when combined with RIFABUTIN.


The metabolism of Mirabegron can be increased when combined with primidone.


The metabolism of carvedilol can be increased when combined with carbamazepine.


The metabolism of MAGNESIUM SULFATE can be increased when combined with nafcillin.


The metabolism of Brivaracetam can be increased when combined with phenytoin.


The metabolism of diazepam can be increased when combined with phenobarbital.


The metabolism of dyphylline can be increased when combined with L-thyroxine.


The metabolism of sibutramine can be increased when combined with pentobarbital.


The metabolism of sertraline can be increased when combined with pentobarbital.


The metabolism of disulfiram can be increased when combined with phenobarbital.


The metabolism of pimozide can be increased when combined with pentobarbital.


The metabolism of Vitamin D3 can be increased when combined with pentobarbital.


The metabolism of tetracycline can be increased when combined with primidone.


The metabolism of nicardipine can be increased when combined with primidone.


The metabolism of dopamine can be increased when combined with RIFAPENTINE.


The metabolism of triamcinolone can be increased when combined with primidone.


The metabolism of efavirenz can be increased when combined with primidone.


The metabolism of testosterone can be increased when combined with primidone.


The metabolism of formoterol can be increased when combined with RIFAPENTINE.


The metabolism of Ramelteon can be increased when combined with RIFAPENTINE.


The metabolism of clorazepate can be increased when combined with primidone.


The metabolism of Iloperidone can be increased when combined with primidone.


The metabolism of cytarabine can be increased when combined with RIFAPENTINE.


The metabolism of Ramelteon can be increased when combined with RIFABUTIN.


The metabolism of flunisolide can be increased when combined with pentobarbital.


The metabolism of PRIMAQUINE can be increased when combined with carbamazepine.


The metabolism of cinnarizine can be increased when combined with thiopental.


The metabolism of nicotine can be increased when combined with pentobarbital.


The metabolism of Cevimeline can be increased when combined with pentobarbital.


The metabolism of indapamide can be increased when combined with Lumacaftor.


The metabolism of ambroxol can be increased when combined with carbamazepine.


The metabolism of ALFENTANIL can be increased when combined with Lumacaftor.


The metabolism of pilocarpine can be increased when combined with carbamazepine.


The metabolism of Arformoterol can be increased when combined with phenobarbital.


The metabolism of Almotriptan can be increased when combined with phenobarbital.


The metabolism of Risedronic acid can be increased when combined with thiamylal.


The metabolism of phenindione can be increased when combined with thiamylal.


The metabolism of Midostaurin can be increased when combined with RIFABUTIN.


The metabolism of Repaglinide can be increased when combined with phenobarbital.


The metabolism of dolasetron can be increased when combined with primidone.


The metabolism of Paricalcitol can be increased when combined with phenobarbital.


The metabolism of tinidazole can be increased when combined with phenobarbital.


The metabolism of Dapagliflozin can be increased when combined with Rifampicin.


The metabolism of Levomilnacipran can be increased when combined with Rifampicin.


The metabolism of Ciclesonide can be increased when combined with Rifampicin.


The metabolism of LESINURAD can be increased when combined with secobarbital.


The metabolism of alosetron can be increased when combined with Rifampicin.


The metabolism of ACENOCOUMAROL can be increased when combined with Rifampicin.


The metabolism of cyclophosphamide can be increased when combined with primidone.


The metabolism of oxiconazole can be increased when combined with Lopinavir.


The metabolism of selegiline can be increased when combined with RIFAPENTINE.


The metabolism of tolterodine can be increased when combined with RIFAPENTINE.